CATALYST BIOSCIENCES LICENSES SEMINAL INTELLECTUAL PROPERTY IN THE FIELD OF PROTEASE THERAPEUTICS

Catalyst Biosciences, Inc. and Torrey Pines Institute for Molecular Studies announced today that they have entered into an exclusive worldwide license agreement for Catalyst's use of the Institute's seminal intellectual property covering protease engineering, selection and optimization. Catalyst is an emerging drug discovery and development company focused on advancing proteases as a new platform for biotherapeutics development in inflammation, cardiovascular disease and other disorders. Torrey Pines Institute is a non-profit research center that conducts major research programs directed towards novel drug discovery technologies.
Yahoo News